LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

LLY

987.3

-1.15%↓

JNJ

239.45

-2.34%↓

ABBV

231.24

-1%↓

NVS

160.31

-2.13%↓

AZN

198.27

-2.09%↓

Search

Fate Therapeutics Inc

Închisă

SectorSănătate

1.45 6.62

Rezumat

Modificarea prețului

24h

Curent

Minim

1.3599999999999999

Maxim

1.47

Indicatori cheie

By Trading Economics

Venit

1.8M

-32M

Vânzări

-372K

1.4M

EPS

-0.27

Marjă de profit

-1,852.384

Angajați

181

EBITDA

-13M

-42M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+179.56% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-1.2M

173M

Deschiderea anterioară

-5.17

Închiderea anterioară

1.45

Sentimentul știrilor

By Acuity

20%

80%

37 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 mar. 2026, 23:39 UTC

Acțiuni populare

Stocks to Watch: Broadcom, StubHub, PepGen, Veeva Systems

4 mar. 2026, 23:20 UTC

Câștiguri

Broadcom Sales Rise as AI Developers Build More Products and Agents -- Update

4 mar. 2026, 21:43 UTC

Câștiguri

Broadcom Logs Higher Sales, Authorizes $10 Billion Buyback Amid Climbing AI Demand

4 mar. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

4 mar. 2026, 23:33 UTC

Market Talk
Evenimente importante

Gold Edges Higher Amid Ongoing U.S.-Iran Conflict -- Market Talk

4 mar. 2026, 23:24 UTC

Market Talk

RBA on Track to Raise Rates, but What's the Rush? -- Market Talk

4 mar. 2026, 22:30 UTC

Câștiguri

Ecopetrol: Distribution Equivalent to a Payout of 50.1% of Ecopetrol S.A.'s Net Income in 2025 >EC

4 mar. 2026, 22:30 UTC

Câștiguri

Ecopetrol: Payment of Dividends Proposed to Be Made No Later Than April 30 >EC

4 mar. 2026, 22:30 UTC

Câștiguri

Ecopetrol: Earnings Distribution Proposes Ordinary Div Distribution of COP110 per Shr >EC

4 mar. 2026, 22:13 UTC

Câștiguri

Vermilion Energy: Expects Full-Yr Production of 118,000 to 122,000 Boe/d (70% Natural Gas) >VET

4 mar. 2026, 22:13 UTC

Câștiguri

Vermilion Energy: Expects 1Q Production to Avg 122,000 to 124,000 Boe/d (70% Natural Gas) >VET

4 mar. 2026, 22:13 UTC

Câștiguri

Vermilion Energy 4Q EPS C$2.86 >VET

4 mar. 2026, 22:04 UTC

Market Talk

RBA Slipping Behind The Curve On Rates -- Market Talk

4 mar. 2026, 21:53 UTC

Câștiguri

Lithium Americas 4Q Rev $66.8M >LAC

4 mar. 2026, 21:53 UTC

Câștiguri

Lithium Americas 4Q Loss/Shr 52c >LAC

4 mar. 2026, 21:52 UTC

Câștiguri

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar. 2026, 21:50 UTC

Câștiguri

These Stocks Are Today's Movers: Moderna, Coinbase, Strategy, CoreWeave, Micron, Sandisk, GitLab, and More -- Barrons.com

4 mar. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 mar. 2026, 21:48 UTC

Câștiguri

Webull 4Q Rev $165.2M >BULL

4 mar. 2026, 21:48 UTC

Câștiguri

Webull 4Q EPS 1c >BULL

4 mar. 2026, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 mar. 2026, 21:45 UTC

Market Talk

Canada Officials Might Need to Intervene to Spur Home Building -- Market Talk

4 mar. 2026, 21:40 UTC

Câștiguri

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar. 2026, 21:36 UTC

Evenimente importante

Iran Conflict Spurs Rebound in U.S. Borrowing Costs -- Update

4 mar. 2026, 21:27 UTC

Câștiguri

Broadcom Earnings Beat Estimates as AI Demand Remains Strong -- Barrons.com

4 mar. 2026, 21:17 UTC

Market Talk

Energy Price Volatility Boosts Case for Climate-Tech Startups -- Market Talk

4 mar. 2026, 21:16 UTC

Câștiguri

Broadcom: Board Authorizes Share-Repurchase Program for Up to $10B of Common Stock >AVGO

4 mar. 2026, 21:15 UTC

Câștiguri

Broadcom 1Q EPS $1.50 >AVGO

4 mar. 2026, 21:15 UTC

Câștiguri

Broadcom 1Q Net $7.35B >AVGO

4 mar. 2026, 21:15 UTC

Câștiguri

Broadcom 1Q Rev $19.31B >AVGO

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

179.56% sus

Prognoză pe 12 luni

Medie 3.83 USD  179.56%

Maxim 7 USD

Minim 2 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

37 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
help-icon Live chat